After Reaching Milestone, Is Ani Pharmaceuticals Inc (NASDAQ:ANIP)’s Short Interest Revealing Something?

May 16, 2018 - By David Engel

Investors sentiment decreased to 1.09 in 2017 Q4. Its down 0.60, from 1.69 in 2017Q3. It is negative, as 13 investors sold ANI Pharmaceuticals, Inc. shares while 43 reduced holdings. 23 funds opened positions while 38 raised stakes. 6.25 million shares or 0.89% less from 6.31 million shares in 2017Q3 were reported.
Violich Cap Mgmt owns 4,140 shares. Riverhead Cap Management Ltd Com accumulated 1,183 shares. Shine Investment Advisory Svcs has invested 0% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Highland Cap Limited Partnership holds 4,400 shares or 0.01% of its portfolio. Kbc Gp Nv reported 16,057 shares. Pacad invested in 2,500 shares or 0.04% of the stock. Cortina Asset Lc accumulated 94,508 shares. Goldman Sachs Gp holds 0% or 35,280 shares. Geode Capital Mgmt Ltd accumulated 0% or 76,978 shares. The New York-based Hutchin Hill Cap L P has invested 0.24% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Ranger Investment Management L P owns 39,487 shares. Cornercap Counsel Inc reported 11,250 shares. Tci Wealth Advsrs reported 15 shares. Thrivent Finance For Lutherans invested in 0% or 5,611 shares. Perkins Mgmt reported 27,000 shares or 1.67% of all its holdings.

Since March 1, 2018, it had 0 insider purchases, and 9 insider sales for $15.78 million activity. MARSHBANKS TRACY also sold $3.87 million worth of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) shares. Another trade for 4,177 shares valued at $258,640 was sold by Marken James G.. Schrepfer Robert W also sold $1.77 million worth of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) shares. Another trade for 23,986 shares valued at $1.47 million was sold by PRZYBYL ARTHUR.

The stock of Ani Pharmaceuticals Inc (NASDAQ:ANIP) registered an increase of 0.5% in short interest. ANIP’s total short interest was 688,400 shares in May as published by FINRA. Its up 0.5% from 685,000 shares, reported previously. With 65,700 shares average volume, it will take short sellers 11 days to cover their ANIP’s short positions. The short interest to Ani Pharmaceuticals Inc’s float is 7.7%.

The stock increased 0.10% or $0.06 during the last trading session, reaching $62.03. About 47,193 shares traded. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has risen 18.93% since May 16, 2017 and is uptrending. It has outperformed by 7.38% the S&P500.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and markets branded and generic prescription pharmaceuticals in the United States. The company has market cap of $731.11 million. It focuses on producing controlled substances, anti-cancer , hormones and steroids, and complex formulations. It currently has negative earnings. The firm offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis.

More important recent ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) news were published by: which released: “Market Trends Toward New Normal in Viacom, Nutanix, ANI Pharmaceuticals, PACCAR, Cabot Oil & Gas, and Box …” on May 07, 2018, also published article titled: “ANI Pharma (ANIP) Agrees to Acquire Generic Products & Other Assets from Amneal Pharmaceuticals LLC and Impax …”, published: “Benzinga’s Daily Biotech Pulse: Valeant Earnings, Lipocine’s FDA Watch, Invivo CFO Departure” on May 08, 2018. More interesting news about ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was released by: and their article: “ANI Pharmaceuticals buying assets from Amneal, Impax” with publication date: April 27, 2018.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: